Third Rock launches biotech targeting 'notoriously difficult' DNA regulators

For drug developers, transcription factors are an attractive target. "Every biotech company that I've been a part of has been interested in at least one or two," said Abbie Celniker, a well-known industry veteran and a partner at the healthcare investment firm Third Rock Ventures. That's been true since the early 1990s, according to Celniker, who's worked at high-profile companies including Novartis, Millennium Pharmaceuticals and Genentech.